Important areas for future research include the development of inhibitors specifically targeting downstream effectors of NF-κB; in particular, enzymes like MMP9 and MnSOD whose expression is significantly correlated with poor prognosis and survival outcome in ccRCC. Here, MMP9 is linked to nonpapillary renal cell carcinoma.